These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 1681057)
1. Enhancement of 4-biphenylacetic acid bioavailability in rats by its beta-cyclodextrin complex after oral administration. Puglisi G; Santagati NA; Ventura CA; Pignatello R; Panico AM; Spampinato S J Pharm Pharmacol; 1991 Jun; 43(6):430-2. PubMed ID: 1681057 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of modified beta-cyclodextrins on pharmacological activity and bioavailability of 4-biphenylacetic acid in rats after oral administration. Puglisi G; Ventura CA; Spadaro A; Campana G; Spampinato S J Pharm Pharmacol; 1995 Feb; 47(2):120-3. PubMed ID: 7602465 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats. Arima H; Adachi H; Irie T; Uekama K; Pitha J Pharm Res; 1990 Nov; 7(11):1152-6. PubMed ID: 2293214 [TBL] [Abstract][Full Text] [Related]
4. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. Nagarsenker MS; Meshram RN; Ramprakash G J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065 [TBL] [Abstract][Full Text] [Related]
5. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. Minami K; Hirayama F; Uekama K J Pharm Sci; 1998 Jun; 87(6):715-20. PubMed ID: 9607948 [TBL] [Abstract][Full Text] [Related]
6. [Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery]. Arima H; Kondo T; Irie T; Hirayama F; Uekama K; Miyaji T; Inoue Y Yakugaku Zasshi; 1992 Jan; 112(1):65-72. PubMed ID: 1578346 [TBL] [Abstract][Full Text] [Related]
7. Meloxicam complexation with beta-cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity. Baboota S; Agarwal SP Pharmazie; 2003 Jan; 58(1):73-4. PubMed ID: 12622261 [No Abstract] [Full Text] [Related]
8. Ethyl ferulate/β-cyclodextrin inclusion complex inhibits edema formation. Cunha FVM; do Nascimento Caldas Trindade G; da Silva Azevedo PS; Coêlho AG; Braz EM; Pereira de Sousa Neto B; de Rezende DC; de Sousa DP; de Assis Oliveira F; Nunes LCC Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111057. PubMed ID: 32600687 [TBL] [Abstract][Full Text] [Related]
9. Preparation and properties of valdecoxib-hydroxypropyl beta-cyclodextrin inclusion complex. Gowrishankar P; Ali M; Baboota S PDA J Pharm Sci Technol; 2007; 61(3):175-82. PubMed ID: 17722484 [TBL] [Abstract][Full Text] [Related]
10. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment. Arima H; Miyaji T; Irie T; Hirayama F; Uekama K Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):582-6. PubMed ID: 8882455 [TBL] [Abstract][Full Text] [Related]
11. In-vitro evaluation of biphenylyl acetic acid-beta-cyclodextrin conjugates as colon-targeting prodrugs: drug release behaviour in rat biological media. Hirayama F; Minami K; Uekama K J Pharm Pharmacol; 1996 Jan; 48(1):27-31. PubMed ID: 8722490 [TBL] [Abstract][Full Text] [Related]
12. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics. Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976 [TBL] [Abstract][Full Text] [Related]
13. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-beta-cyclodextrin complexation in healthy volunteers. Panini R; Vandelli MA; Forni F; Pradelli JM; Salvioli G Pharmacol Res; 1995; 31(3-4):205-9. PubMed ID: 7630860 [TBL] [Abstract][Full Text] [Related]
14. Enhanced oral bioavailability of antiinflammatory drug flurbiprofen in rabbits by tri-O-methyl-beta-cyclodextrin complexation. Otagiri M; Imai T; Uekama K J Pharmacobiodyn; 1982 Dec; 5(12):1027-9. PubMed ID: 7169606 [TBL] [Abstract][Full Text] [Related]
15. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects. Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132 [TBL] [Abstract][Full Text] [Related]
16. Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin. Nair AB; Attimarad M; Al-Dhubiab BE; Wadhwa J; Harsha S; Ahmed M Drug Deliv; 2014 Nov; 21(7):540-7. PubMed ID: 24215288 [TBL] [Abstract][Full Text] [Related]
17. The pharmacologic activity of complexes and mixtures with copper and salicylates or aminopyrine following oral dosing in rats. Korolkiewicz Z; Hać E; Gagało I; Gorczyca P; Lodzińska A Agents Actions; 1989 Mar; 26(3-4):355-9. PubMed ID: 2735226 [TBL] [Abstract][Full Text] [Related]
18. Beta-cyclodextrins enhance bioavailability of pilocarpine. Freedman KA; Klein JW; Crosson CE Curr Eye Res; 1993 Jul; 12(7):641-7. PubMed ID: 8222723 [TBL] [Abstract][Full Text] [Related]